Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by
open-label phase, to evaluate the effects of adalimumab compared to placebo on the change
from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis
(MPS) I or II.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center